# US 2002/0054863 A1 · Method of treating cancerous tumors with a dendritic-platinate drug delivery system and a process for preparing that system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0054863 A1
- Document ID: US20020054863A1
- Status: Published application
- Kind: A1
- Application number: 09/881,126
- Filed: 2001-06-14
- Published: 2002-05-09
- Earliest claimed: 1997-07-07
- Assignees: The Dow Chemical Company
- Inventors: Navid Malik; Ruth Duncan
- Web page: https://patentgrep.com/patent/US20020054863A1

## CPC

- A61K 47/6949: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C08G 69/00: Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule (products obtained from isocyanates or isothiocyanates C08G18/00; polyamide-imides C08G73/14)
- C08G 69/02: Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G 83/003: {Dendrimers}
- Y10S 424/16: Dendrimers and dendritic polymers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Dendritic polymer conjugates which are useful drug delivery systems for carrying platinum containing anti-tumor agents to malignant tumors are prepared by obtaining a dendritic polymer having functional groups which are accessible to a platinum containing compound capable of interacting with the functional groups, contacting the dendritic polymer with the platinum containing compound, and reacting the dendritic polymer with the platinum containing compound. The dendritic polymer platinates may be administered intravenously, orally, parentally, subcutaneously or topically to an animal having a malignant tumor in an amount which is effective to inhibit growth of the malignant tumor. The dendritic polymer platinates exhibit high drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, reduced toxicity, and improved anti-tumor activity in vivo.

## Claims

### Claim 1

A dendritic polymer conjugate, comprising:
a dendritic polymer conjugated to a platinum containing compound having a therapeutic effect on malignant tumors.

### Claim 2 (depends on 1)

The dendritic polymer conjugate of claim 1, wherein the dendritic polymer is a dendrimer.

### Claim 3 (depends on 1)

The dendritic polymer conjugate of claim 1 in which the dendritic polymer which is conjugated to the platinum containing compound includes anionic terminal functional groups.

### Claim 4 (depends on 3)

The dendritic polymer conjugate of claim 3 in which the anionic functional groups are carboxylic acid functional groups.

### Claim 5 (depends on 1)

The dendritic polymer conjugate of claim 1, wherein the dendritic polymer is a polyamidoamine dendrimer having carboxylate functional groups.

### Claim 6 (depends on 1)

The dendritic polymer conjugate of claim 1 in which the dendritic polymer is a polypropylamine having carboxylate functional groups.

### Claim 7 (depends on 1)

The dendritic polymer conjugate of claim 1 in which the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atoms of two amino ligands, which may be the same of different, the amine ligands being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

### Claim 8 (depends on 1)

The dendritic polymer conjugate of claim 1 in which the platinum containing compound is cisplatin.

### Claim 9 (depends on 2)

The dendritic polymer conjugate of claim 2 in which the dendrimer has carboxylate function groups.

### Claim 10 (depends on 9)

The dendritic polymer conjugate of claim 9 in which the dendritic polymer is a polyamidoamine.

### Claim 11 (depends on 9)

The dendritic polymer conjugate of claim 9 in which the dendrimer is a polypropylamine.

### Claim 12 (depends on 9)

The dendritic polymer conjugate of claim 9 in which the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

### Claim 13 (depends on 9)

The dendritic polymer conjugate of claim 9 in which the platinum containing compound is cisplatin.

### Claim 14 (depends on 10)

The dendritic polymer conjugate of claim 10 in which the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

### Claim 15 (depends on 10)

The dendritic polymer conjugate of claim 10 in which the platinum containing compound is cisplatin.

### Claim 16 (depends on 11)

The dendritic polymer conjugate of claim 11 in which the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

### Claim 17 (depends on 11)

The dendritic polymer conjugate of claim 11 in which the platinum containing compound is cisplatin.

### Claim 18 (depends on 1)

The dendritic polymer conjugate of claim 1, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is from about 100:1 to about 1:1.

### Claim 19 (depends on 1)

The dendritic polymer conjugate of claim 1, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is about 35:1.

### Claim 20

A method of preparing a dendritic polymer-platinate, comprising:
providing a dendritic polymer having functional groups which are accessible to a platinum containing compound capable of interacting with the functional groups;
contacting the dendritic polymer with a platinum containing compound; and
reacting the dendritic polymer with the platinum containing compound.

### Claim 21 (depends on 20)

The method of claim 20, wherein the dendritic polymer is contacted with the platinum containing compound in a solvent.

### Claim 22 (depends on 21)

The method of claim 21, wherein the solvent is primarily comprised of water.

### Claim 23 (depends on 20)

The method of claim 20, wherein the dendritic polymer is a dendrimer.

### Claim 24 (depends on 20)

The method of claim 20, wherein the dendritic polymer has anionic functional groups.

### Claim 25 (depends on 24)

The method of claim 24, wherein the anionic groups are carboxylate groups.

### Claim 26 (depends on 20)

The method of claim 20, wherein the dendritic polymer is a polyamidoamine dendrimer.

### Claim 27 (depends on 20)

The method of claim 20, wherein the dendritic polymer is a polypropylamine.

### Claim 28 (depends on 20)

The method of claim 20, wherein the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

### Claim 29 (depends on 20)

The method of claim 20, wherein the platinum containing compound is cisplatin.

### Claim 30 (depends on 20)

The method of claim 20, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is from about 100:1 to about 1:1.

### Claim 31 (depends on 20)

The method of claim 20, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is about 35:1.

### Claim 32

A method for treatment of cancerous tumors in mammals, comprising administering a therapeutically effective quantity of a dendritic polymer-platinate compound to a mammal having a cancerous tumor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the dendritic polymer is a dendrimer.

### Claim 34 (depends on 32)

The method of claim 32, wherein the dendritic polymer has anionic functional groups.

### Claim 35 (depends on 34)

The method of claim 34, wherein the anionic groups are carboxylate groups.

### Claim 36 (depends on 32)

The method of claim 32, wherein the dendritic polymer is a polyamidoamine dendrimer.

### Claim 37 (depends on 32)

The method of claim 32, wherein the dendritic polymer is a polypropylamine.

### Claim 38 (depends on 32)

The method of claim 32, wherein the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

### Claim 39 (depends on 32)

The method of claim 32, wherein the platinum containing compound is cisplatin.

### Claim 40 (depends on 32)

The method of claim 32, wherein the dendritic polymer-platinate compound is administered parentally.

### Claim 41 (depends on 32)

The method of claim 32, wherein the dendritic polymer-platinate compound is administered intravenously or intraperitoneally.

### Claim 42 (depends on 32)

The method of claim 32, wherein the dendritic polymer-platinate compound is administered orally.

### Claim 43 (depends on 32)

The method of claim 32, wherein the dendritic polymer-platinate compound is administered topically.

### Claim 44 (depends on 32)

The method of claim 32, wherein the dendritic polymer-platinate compound is administered intraperitoneally.

### Claim 45 (depends on 32)

The method of claim 32, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is from about 100:1 to about 1:1.

### Claim 46 (depends on 32)

The method of claim 32, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is about 35:1.
